康恩貝(600572.SH):布洛芬顆粒通過仿製藥一致性評價
格隆匯3月20日丨康恩貝(600572.SH)公佈,近日,公司收到國家藥品監督管理局頒發的關於布洛芬顆粒的《藥品補充申請批件》,該藥品通過仿製藥一致性評價。
布洛芬顆粒作為常用的解熱鎮痛藥品,已列入《國家醫保目錄(2019年版)》,是醫保甲類藥品。主要用於緩解輕至中度疼痛如頭痛、關節痛、偏頭痛、牙痛、肌肉痛、神經痛、痛經;也用於普通感冒或流行性感冒引起的發熱。
截至本公告披露日,通過國家藥監局一致性評價的布洛芬顆粒廠家有康恩貝和揚子江藥業集團江蘇製藥股份有限公司、石藥集團歐意藥業有限公司三家企業。
米內網終端數據顯示:相應零售和醫療終端市場2018年布洛芬口服制劑銷售額26.07億元,其中散劑顆粒劑銷售額約2億元,本公司的布洛芬顆粒劑銷售額為1,947萬元,佔散劑顆粒劑市場份額的9.74%。截至目前,本公司針對該藥品一致性評價已投入研發費用約人民幣1,438萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.